The following is a summary of “Cutaneous manifestations of Fabry disease: A systematic review,” published in the March 2025 ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Around 1,000 patients with rare diseases are registered with Centres of Excellence in India. The government allocated ...

Chardan took over coverage of uniQure (QURE) with a Buy rating and price target of $38. The analyst, who cites the potential of the company’s ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

"Health being a state subject, the primary responsibility of providing healthcare services is that of state governments. However, to mitigate the challenges posed by rare diseases in India, the Union ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 13.07%, which has investors questioning if this is right time to buy.

Gaucher disease is a genetic disorder when the body is unable to break down certain fats, leading to fat accumulation in the ...

Learn more about whether Alvotech or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report, ...

For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Chiesi’s approach to ...